(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer session included a presentation by Dr. Bertrand Tombal discussing a subgroup analysis of the phase 3 HERO study assessing geographical efficacy and safety of relugolix versus leuprolide among men with advanced prostate cancer. Androgen deprivation therapy is a cornerstone of prostate cancer treatment and is usually given with gonadotropic-releasing hormone (GnRH) agonists or GnRH receptor antagonists. Relugolix, the once-daily oral GnRH receptor antagonist, demonstrated suppression of testosterone to castrate levels in 96.7% of patients, and a 54% lower risk of major adverse cardiovascular events relative to leuprolide in the HERO study.1 At the ESMO 2021 meeting, Dr. Tombal and colleagues presented results characterizing the geographical impact on the efficacy and safety of relugolix versus leuprolide in advanced prostate cancer, a subgroup analysis of HERO was undertaken.